ORAMED PHARMACEUTICALS INC.

OraMed Pharmaceuticals is a pharmaceutical company focused on researching and developing innovative pharmaceutical solutions, particularly those involving the oral delivery of therapeutic proteins. The company has developed an oral dosage form designed to withstand the gastrointestinal tract and deliver active insulin or other proteins without chemically or biologically modifying them, and it is designed to be safe to ingest. OraMed also makes strategic investments in healthcare and life sciences companies that align with its long-term business objectives and technology focus. In the second half of 2026, OraMed intends to start a 60-patient, US-based clinical trial to validate its oral insulin formulation. This trial will be conducted by OraTech. On January 22, 2024, OraMed, along with its wholly-owned subsidiary Oramed Ltd., entered into a joint venture agreement with Hefei Tianhui Biotech Co., Ltd. (HTIT) and its subsidiary Technowl Limited (HTIT Sub.) to establish OraTech. OraTech will concentrate on developing and commercializing products based on OraMed's oral insulin and POD™ technology, leveraging HTIT's manufacturing capabilities.